MX2020006585A - Anticuerpos que se unen a ctla-4 y usos de los mismos. - Google Patents

Anticuerpos que se unen a ctla-4 y usos de los mismos.

Info

Publication number
MX2020006585A
MX2020006585A MX2020006585A MX2020006585A MX2020006585A MX 2020006585 A MX2020006585 A MX 2020006585A MX 2020006585 A MX2020006585 A MX 2020006585A MX 2020006585 A MX2020006585 A MX 2020006585A MX 2020006585 A MX2020006585 A MX 2020006585A
Authority
MX
Mexico
Prior art keywords
antibodies
bind
ctla
preparing
human
Prior art date
Application number
MX2020006585A
Other languages
English (en)
Spanish (es)
Inventor
Yun He
Xin Gan
Yuqiang Shen
Jiuqiao Zhao
Yiping Rong
Frank Grosveld
Dubravka Drabek
Haperen Marinus Van ( Rien)
Rick Janssens
Original Assignee
Harbour Biomed Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harbour Biomed Shanghai Co Ltd filed Critical Harbour Biomed Shanghai Co Ltd
Publication of MX2020006585A publication Critical patent/MX2020006585A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2020006585A 2017-12-20 2018-12-19 Anticuerpos que se unen a ctla-4 y usos de los mismos. MX2020006585A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762607917P 2017-12-20 2017-12-20
PCT/CN2018/122190 WO2019120232A1 (en) 2017-12-20 2018-12-19 Antibodies binding ctla-4 and uses thereof

Publications (1)

Publication Number Publication Date
MX2020006585A true MX2020006585A (es) 2020-09-25

Family

ID=66994401

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006585A MX2020006585A (es) 2017-12-20 2018-12-19 Anticuerpos que se unen a ctla-4 y usos de los mismos.

Country Status (19)

Country Link
US (2) US11098122B2 (enExample)
EP (2) EP4295915A3 (enExample)
JP (2) JP7087107B2 (enExample)
KR (1) KR102476887B1 (enExample)
CN (2) CN111655728B (enExample)
AU (1) AU2018391831B2 (enExample)
BR (1) BR112020012364A2 (enExample)
CA (1) CA3085861C (enExample)
DK (1) DK3710484T5 (enExample)
ES (1) ES2965187T3 (enExample)
FI (1) FI3710484T3 (enExample)
IL (1) IL275391B2 (enExample)
MX (1) MX2020006585A (enExample)
PH (1) PH12020550933A1 (enExample)
PL (1) PL3710484T3 (enExample)
RU (1) RU2756100C1 (enExample)
SG (1) SG11202005692WA (enExample)
WO (1) WO2019120232A1 (enExample)
ZA (1) ZA202003641B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202005692WA (en) * 2017-12-20 2020-07-29 Harbour Biomed Shanghai Co Ltd Antibodies binding ctla-4 and uses thereof
WO2020127377A1 (en) 2018-12-21 2020-06-25 Ose Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
KR20220088428A (ko) * 2019-09-26 2022-06-27 주식회사 에스티큐브앤컴퍼니 글리코실화된 ctla-4에 대해 특이적인 항체 및 이의 사용 방법
TW202136287A (zh) 2019-12-17 2021-10-01 法商Ｏｓｅ免疫治療公司 包含il-7變體之雙官能分子
WO2022112198A1 (en) 2020-11-24 2022-06-02 Worldwide Innovative Network Method to select the optimal immune checkpoint therapies
CN112569183B (zh) * 2020-12-11 2022-12-09 上海赛金生物医药有限公司 一种抗ctla-4抗体及融合蛋白的制剂
MX2023011964A (es) 2021-04-09 2024-01-08 Ose Immunotherapeutics Nuevo andamio para moléculas bifuncionales con propiedades mejoradas.
EP4320156A1 (en) 2021-04-09 2024-02-14 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
TWI903067B (zh) * 2021-04-21 2025-11-01 中國商和鉑醫藥（上海）有限責任公司 結合ctla-4的抗體及其用途
WO2024003360A1 (en) 2022-07-01 2024-01-04 Institut Curie Biomarkers and uses thereof for the treatment of neuroblastoma
EP4565610A1 (en) 2022-08-02 2025-06-11 Ose Immunotherapeutics Multifunctional molecule directed against cd28
CN120019078A (zh) * 2022-09-02 2025-05-16 西奇利德股份有限公司 抗ctla-4单克隆抗体及其用途
WO2024200820A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Method of synthesis of targeted lipid nanoparticle and uses thereof
JP2026512425A (ja) 2023-03-30 2026-04-16 オーエスイー・イミュノセラピューティクス 免疫細胞増強分子の発現のための活性化免疫細胞に標的化された脂質ベースのナノ粒子及びその使用
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer
WO2026068705A1 (en) 2024-09-26 2026-04-02 Ose Immunotherapeutics Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK368882A (da) 1981-08-25 1983-02-26 Alan John Kingsman Expessions vektorer
US4579821A (en) 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US4486533A (en) 1982-09-02 1984-12-04 St. Louis University Filamentous fungi functional replicating extrachromosomal element
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
US4977092A (en) 1985-06-26 1990-12-11 Amgen Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US5139936A (en) 1983-02-28 1992-08-18 Collaborative Research, Inc. Use of the GAL1 yeast promoter
US4661454A (en) 1983-02-28 1987-04-28 Collaborative Research, Inc. GAL1 yeast promoter linked to non galactokinase gene
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
CA1280080C (en) 1984-12-06 1991-02-12 Jacques Oberto Promoters for the expression of foreign genes in yeast, plasmids comprising them, and uses thereof for the production of polypeptides
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US5063154A (en) 1987-06-24 1991-11-05 Whitehead Institute For Biomedical Research Pheromone - inducible yeast promoter
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5162228A (en) 1988-12-28 1992-11-10 Takeda Chemical Industries, Ltd. Gylceraldehyde-3-phosphate dehydrogenase gene and promoter
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5162222A (en) 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5298418A (en) 1991-09-16 1994-03-29 Boyce Thompson Institute For Plant Research, Inc. Cell line isolated from larval midgut tissue of Trichoplusia ni
WO1994006463A1 (en) 1992-09-14 1994-03-31 Pfizer Inc Immortalized cells and uses therefor
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
US5716808A (en) 1995-11-09 1998-02-10 Zymogenetics, Inc. Genetic engineering of pichia methanolica
US5955349A (en) 1996-08-26 1999-09-21 Zymogenetics, Inc. Compositions and methods for producing heterologous polypeptides in Pichia methanolica
CN1230997A (zh) 1996-07-17 1999-10-06 津莫吉尼蒂克斯公司 甲醇毕赤酵母的转化
US5736383A (en) 1996-08-26 1998-04-07 Zymogenetics, Inc. Preparation of Pichia methanolica auxotrophic mutants
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
ES2706547T3 (es) * 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
AU2001233027A1 (en) * 2000-01-27 2001-08-07 Genetics Institute, Llc Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
CA2658221C (en) * 2001-04-27 2012-11-27 Kyowa Kirin Co., Ltd. Anti-cd40 monoclonal antibody
KR100845354B1 (ko) * 2004-03-26 2008-07-09 화이자 프로덕츠 인코포레이티드 항－ｃｔｌａ－4 항체의 용도
EP1776383B1 (en) 2004-07-22 2014-08-20 Erasmus University Medical Center Rotterdam Binding molecules
US20060240006A1 (en) * 2005-04-20 2006-10-26 Chishih Chu Novel antibody structures derived from human germline sequences
MX2009005189A (es) * 2006-11-15 2009-06-30 Medarex Inc Anticuerpos humanos monoclonales para btla y metodos de uso.
GB0903325D0 (en) * 2009-02-26 2009-04-08 Univ Aberdeen Antibody molecules
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
GB201103955D0 (en) * 2011-03-09 2011-04-20 Antitope Ltd Antibodies
KR101535341B1 (ko) * 2012-07-02 2015-07-13 한화케미칼 주식회사 Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도
CN104292334B (zh) * 2014-04-25 2018-11-27 河南省健康伟业生物医药研究股份有限公司 一种全人源抗ctla-4单克隆抗体、制备方法及应用
CN114014930A (zh) * 2015-02-13 2022-02-08 索伦托药业有限公司 结合ctla4的抗体治疗剂
CN106188297B (zh) 2015-07-20 2019-09-27 广西医科大学 抗CTLA-4的纳米抗体Nb91及其制备方法与应用
CN106220732B (zh) * 2015-07-20 2019-05-21 广西医科大学 抗CTLA-4的纳米抗体Nb16及其制备方法与应用
CN106046164B (zh) * 2015-07-20 2019-10-25 广西医科大学 抗CTLA-4的纳米抗体Nb36及其制备方法与应用
CN106046165B (zh) 2015-07-20 2019-05-21 广西医科大学 抗CTLA-4的纳米抗体Nb30及其制备方法与应用
CN107400166A (zh) * 2016-05-19 2017-11-28 苏州康宁杰瑞生物科技有限公司 针对ctla4的单域抗体及其衍生蛋白
SG11202005692WA (en) * 2017-12-20 2020-07-29 Harbour Biomed Shanghai Co Ltd Antibodies binding ctla-4 and uses thereof

Also Published As

Publication number Publication date
ES2965187T3 (es) 2024-04-11
JP2022120064A (ja) 2022-08-17
JP7087107B2 (ja) 2022-06-20
DK3710484T3 (da) 2023-11-27
PL3710484T3 (pl) 2024-03-25
WO2019120232A1 (en) 2019-06-27
US20190202914A1 (en) 2019-07-04
IL275391A (en) 2020-07-30
FI3710484T3 (fi) 2023-11-20
CN111655728B (zh) 2022-02-22
JP2021508255A (ja) 2021-03-04
US20220002414A1 (en) 2022-01-06
US11098122B2 (en) 2021-08-24
NZ765588A (en) 2024-08-30
KR102476887B1 (ko) 2022-12-13
WO2019120232A8 (en) 2021-03-18
EP4295915A2 (en) 2023-12-27
CN114409786A (zh) 2022-04-29
CA3085861A1 (en) 2019-06-27
PH12020550933A1 (en) 2021-05-17
US12240905B2 (en) 2025-03-04
IL275391B2 (en) 2025-05-01
DK3710484T5 (da) 2024-08-26
SG11202005692WA (en) 2020-07-29
CN111655728A9 (zh) 2021-08-20
EP3710484B1 (en) 2023-10-25
KR20200101422A (ko) 2020-08-27
AU2018391831B2 (en) 2022-08-04
AU2018391831A1 (en) 2020-07-09
CN111655728A (zh) 2020-09-11
CN114409786B (zh) 2025-02-11
IL275391B1 (en) 2025-01-01
EP3710484A4 (en) 2021-12-15
BR112020012364A2 (pt) 2020-11-24
JP7464300B2 (ja) 2024-04-09
EP3710484A1 (en) 2020-09-23
RU2756100C1 (ru) 2021-09-28
EP4295915A3 (en) 2024-05-22
CA3085861C (en) 2023-09-26
ZA202003641B (en) 2022-08-31

Similar Documents

Publication Publication Date Title
CY1125260T1 (el) Παραγοντες δεσμευσης tigit και χρησεις τους
PH12020550933A1 (en) Antibodies binding ctla-4 and uses thereof
MX2021002970A (es) Proteinas de union a nkg2d, cd16 y un antigeno asociado a tumor.
CO2018001624A2 (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
CL2018001565A1 (es) Inmunoglobulinas conjugadas con lisina c-terminal
MX393066B (es) Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos.
MX2016009555A (es) Proteinas de union y metodos para utilizarlas.
MX2018015853A (es) Anticuerpos multiespecificos frente a los grupos de diferenciacion 40 y 137 (cd40 y cd137).
CL2016002667A1 (es) Anticuerpos anti-rnf43 novedosos y métodos para su uso
MX2021002690A (es) Anticuerpos anti-avb8 y composiciones y usos de los mismos.
BR112018014760A2 (pt) anticorpos anti-ror1, anticorpos biespecíficos para ror1 x cd3 e métodos de uso dos mesmos
DOP2017000052A (es) Nuevos anticuerpos anti-mfi2 y metodos de uso
AR106583A1 (es) Anticuerpos que se unen específicamente a pd-1, tim-3 o pd-1 y tim-3 y sus usos
MX2019014000A (es) Una proteína que se une a nkg2d, cd16 y un antígeno asociado a un tumor.
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use
MX2018007817A (es) Nuevos anticuerpos anti-mmp16 y metodos para su uso.
MX2018007818A (es) Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso.
CO2019003759A2 (es) Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos
AR101486A1 (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso
AR101671A1 (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso
AR107223A1 (es) Anticuerpos dirigidos contra upk1b y métodos para su uso
AR102495A1 (es) Anticuerpos contra el dominio 3 de la inmunoglobulina y de la mucina del linfocito t (tim3) y métodos de uso